The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 4
Started
2018-05-01
Last updated
2023-12-11
Condition(s) studied
Graves DiseaseRelapseTreatmentDrug Withdrawal
Investigational drug(s) / intervention(s)
Methimazole
Methimazole: Methimazole used in this study was produced by Merck, Germany, and its trade name is Thyrozol. The specification of this drug is 10mg/ tablet, and its validity period is 36 months. It was approved by FDA in 2009 and listed in China in 2011.
Study summary
In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal were evaluated. At the same time, the changes of immune indexes and inflammatory factors in the regulation process were evaluated. This study is a phase IV clinical study designed and carried out by the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), which is a randomized, open and routine treatment group with parallel control.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Graves hyperthyroidism (responsible for doctors' clinical diagnosis)
* Age 18-65, for both men and women
* Thyroid receptor antibody (TRAb) was positive
* Take part in this research voluntarily and sign the informed consent form
Exclusion Criteria:
* Those who have used glucocorticoid or other immunosuppressants for a long time within 3 months before being selected
* Those who have participated in any other drug trials within 3 months before being selected
* Subjects who are participating in clinical research of other drugs
* Patients with a history of malignant tumors
* Ill-controlled hypertension: diastolic blood pressure≥100mmHg, systolic blood pressure ≥160 mmHg
* Blood routine: the total number of white blood cells \< 3.0×109 or neutrophils \< 1.5× 109
* Other thyroid diseases: such as subacute thyroiditis, thyroid nodules, high-function adenoma
* Alanine aminotransferase(ALT) or aspartate amino transferase(AST) is greater than 2 times of the normal upper limit; When ALT or AST is less than 2 times of the normal upper limit, and the test of hepatitis B two half-and-half positive
* Renal insufficiency: serum creatinine is higher than the upper limit of normal value
* Patients with heart failure
* Patients with coronary heart disease
* Patients with other autoimmune diseases
* Patients who are known to be allergic to any component of this medicine are allergic to the active ingredients or any auxiliary materials in the prescription
* Patients with multiple drug allergies, allergic diseases, people with high sensitivity and drug addicts
* Alcoholism, mental disorder or other observers who are not suitable for drug testing
* Pregnant and lactating women cannot rule out the possibility of pregnancy
* Taking any medicine with unknown ingredients or using traditional Chinese medicine, the researcher judges the medicine that may affect the curative effect of hyperthyroidism
* According to the researcher's judgment, other medical history that reduces the possibility of joining the group or complicates the joining of the group, such as frequent changes in the working environment, may easily lead to lost follow-up.
Rejection Criteria:
* The compliance of this clinical trial protocol is \< 80% or \> 120%;
* Those who did not meet the inclusion criteria or the exclusion criteria were found during the experiment;
* Those who can't cooperate, including those who can't complete the whole course of treatment, don't complete the follow-up as planned, and increase or decrease adjuvant drugs at will;
* During the trial, use other drugs that may affect the curative effect of this trial.
Termination of Research Criteria:
* Those who are allergic or intolerant to this drug;
* Adverse reactions or serious adverse events that patients can't tolerate occur;
* Pregnant women of childbearing age in the experiment;
* Other diseases appear during the treatment, and the treatment of accompanying diseases will interfere with the clinical observers of this medicine;
* The researcher thinks it is inappropriate to continue the experiment.
Primary outcome measure(s)
Cumulative recurrence rate between conventional treatment group and intensive treatment group after two years of withdrawal. — Up to 2 years after drug withdrawal Patients took medicine according to the course of treatment. Relapse occurs when the thyroid function returns to hyperthyroidism within 2 years after the drug is stopped.
Number of patients with no adverse reactions during the treatment of Graves' disease — Within the treatment period (average 2 years) The patient completed the methimazole treatment, and there were no adverse reactions that needed to be stopped. Adverse reactions refer to any symptoms, syndromes or diseases that affect patients' health during clinical research and observation, and also include clinically relevant situations found in the laboratory or other diagnostic processes, such as unplanned diagnosis and treatment measures, withdrawal from research, or clinically significant laboratory examination items. Blood routine, liver function, kidney function and adverse reactions will be recorded during the follow-up.
Trial sites (1)
Facility
City
Region
Status
the First Affiliated Hospital of Nanjing Medical University
Nanjing
China
Recruiting
More The First Affiliated Hospital with Nanjing Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.